Standard BioTools Inc. (LAB) Stock Score, Valuation & Financial Research
Standard BioTools Inc. is in the Healthcare sector and Medical - Specialties industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 28/100.
Quick answer for LAB
Standard BioTools Inc. currently has a Wall Street Score of 28/100. The stored market price is $0.71. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Standard BioTools Inc. does
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by pres
LAB financial snapshot
- Wall Street Score:
- 28/100
- Current price:
- $0.71
- Market capitalization:
- $277.6M
- Revenue:
- $86.3M
- Net income:
- $-94.1M
- Free cash flow:
- $-82.7M
- Cash:
- $265.8M
- Total debt:
- $29.5M
- EPS:
- -0.20
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 4/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-82.7M, showing cash burn in the current stored period.
- The balance sheet shows $265.8M of cash versus $29.5M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research LAB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.